33 slides from Advanced Enzyme Technologies's earnings presentation, Nov 12, 2025
Slide 1: Stock exchange filing cover letter: Earnings Presentation
^ franced enzymes Where EI\IZYME is Life Advanced Enzyme Technologies Ltd. CIN: L24200MH1989PLC051018 Sun Magnetica, A wing, 5 th Floor, LIC Service Road, Louiswadi, Thane ( W ) -400 604, India Tel: + 91-22-4170 3200, Fax: + 91 -22- 2583 5159 Email: info@ advancedenzymes.com, www.advancedenzymes.com
Slide 2: Advanced Enzyme Technologies Limited Earnings Presentation, November 2025
advanced enzymes Where ENZYME is Life Advanced Enzyme Technologies Limited Earnings Presentation | November 2025
Slide 3: Safe Harbour Statement
Safe Harbour Statement ^ Manced enzymes WhPiP FN7YMF /5 Lite This presentation contains forward-looking statements that reflect management’s current views with respect to certain future events and potential financial performance. Forward-looking statements are other than statements of historical fac
Slide 4: Table of Contents
^ Mancecl enzymes Where ENZYME is Life 2 Performance Summary | Q2 FY26 Business Performance PAGE: 4 PAGE: 07 4 Geographical Performance Result Summary | Q2 FY26 PAGE: 11 PAGE: 12 6 Unique Investment Case Focus Area Going Ahead PAGE: 26 PAGE: 30 TABLE OF CONTENTS Shareholders’ Information PAGE: 31 Ea
Slide 5: Results Summary - Q2 FY26 (Consolidated) Y-o-Y
Results Summary - Q 2 FY26 (Consolidated) Y-o-Y Advanced enzy 77705 >: \ IV: Revenue* (₹ mn) EBITDA (₹ mn) PAT (₹ mn) I I 42% 601 34% I 1,845 26% 447 1,461 424 334 Q2 FY25 Q2 FY26 Q2 FY25 Q2 FY26 Q2 FY25 Q2 FY26 Revenue grew by 26% on y-o-y basis to EBITDA grew by 42% to ₹ 601 million in the PAT inc
Slide 6: Results Summary - Q2 FY26 (Consolidated) Q-o-Q
Results Summary - Q 2 FY26 (Consolidated) Q-o-Q Advanced enzyi77705 :\> IV Revenue* (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 6% 11% I I I 1,859 1% 1,845 564 601 404 447 Q1 FY26 Q2 FY26 Q1 FY26 Q2 FY26 Q1 FY26 Q2 FY26 Revenue de-grew by 1% on q-o-q basis to ₹ 1,845 million EBITDA grew by 6% to ₹ 601 million i
Slide 7: Results Summary - H1 FY26 (Consolidated) YTD
Results Summary - H1 FY 26 (Consolidated) YTD Advanced enzyi77705 :\> IV Revenue* (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 24% 25% I I I 23% 3,704 1,165 852 3,006 936 684 H1 FY25 H1 FY26 H1 FY25 H1 FY26 H1 FY25 H1 FY26 Revenue grew by 23% on YTD basis to ₹ EBITDA grew by 24% to ₹ 1,165 million in PAT increas
Slide 8: Human Nutrition
Human Nutrition Advanced enzvi77705 :\ > IV (₹ in (₹ in Million) Million) Q2 FY26 Q2 FY25 H1 FY26 H1 FY25 1,212 992 of Sales +21 % 2,434 2,003 of Sales Commentary: Commentary: 1,221 1,212 1,107 1,059 1,024 1,031 1,012 992 1,018 • The human nutrition segment contributed around • The human nutrition s
Slide 9: Animal Nutrition
Animal Nutrition Advanced enzvi77705 :\ > IV (₹ in (₹ in Million) Million) Q2 FY26 Q2 FY25 H1 FY26 H1 FY25 193 181 of Sales +28% 452 353 of Sales Commentary: Commentary: 260 • The animal nutrition segment contributed around • The animal nutrition segment contributed around 10% during the quarter to
Slide 10: Industrial Bio-processing
Industrial Bio-processing Advanced enzvi77705 :\ > IV Q2 FY26: ₹206 mn Food (₹ in (₹ in Million) Million) 11% Q2 FY26 Q2 FY25 H1 FY26 H1 FY25 Q2 FY26: ₹49 mn 255 168 of Sales +17% 491 419 of Sales Non-Food 3% Commentary: Commentary: 321 • The Industrial Bio-Processing segment contributed 14% • The I
Slide 11: Specialized Manufacturing
Specialized Manufacturing ^^ ancecl enzymes Where ENZYME is Life (₹ in (₹ in J Million) Million) Q2 FY26 Q2 FY25 H1 FY26 H2 FY25 +54% 185 120 of Sales +42% 327 230 of Sales * Commentary: Commentary: 185 • This segment contributed about 10% during the • This segment contributed about 9% during the fi
Slide 12: Geographical performance
Geographical performance ^clvanced enzvi77705 :\ > IV m • * ' 3 India Americas Europe Asia* Rest of the World 48% 30% 6% 14% 2% I Q2 FY26 887 Q2 FY26 554 Q2 FY26 116 Q2 FY26 256 Q2 FY26 32 Q2 FY26 Q2 FY25 703 Q2 FY25 571 Q2 FY25 54 Q2 FY25 101 Q2 FY25 32 +26% -3% 114% +153% +1% 50% 30% 6% 12% 2% I H
Slide 13: Profit & Loss (Consolidated) - Q2 FY26 & H1 FY26
Profit & Loss (Consolidated) - Q 2 FY 26 & HI FY 26 Advanced enzvi77705 :\ > IV (₹ in Million) Q2 FY26 Q1 FY26 Q2 FY25 Y-o-Y Q-o-Q H1 FY26 H1 FY25 Particulars Y-o-Y (%) Un-Audited Un-Audited Un-Audited (%) (%) Un-Audited Un-Audited Income from Operations 1,845 1,859 1,461 26% -1% 3,704 3,006 23% Exp
Slide 14: Result summary - FY25 (Consolidated) Y-o-Y
Result summary - FY25 (Consolidated) Y-o-Y Advanced enzy 77705 >: \ IV: (₹ in Million) Revenue* (? mn) EBITDA (? mn) PAT (? mn) 6,239 02% 6,369 2,045 05% 1,944 1,370 02% 1,340 FY24 FY25 FY24 FY25 FY24 FY25 Human HC Animal HC Bio Processing Specialized Manufacturing -03% +12% +06% +30% FY25 FY24 FY25
Slide 15: Revenue Split - FY25 vs. FY24
Revenue Split - FY25 vs. FY24 Advanced enzyi77705 :\> IV FY24 8% 7% 16% 15% Product Product Category-wise (%) Category-wise (%) 11% 12% 64% 67% Human HC Animal HC Bio-Processing Specialized Manufacturing Human HC Animal HC Bio-Processing Specialized Manufacturing 3% 3% 9% 7% 5% 6% Geographical Geogr
Slide 16: Strong Financial Performance - FY25
Strong Financial Performance - FY25 Advanced enzy 77705 > : \ IV : Revenue from Operations EBIDTA & EBIDTA Margin (%) 6,239 6,369 2,500 46% 50% L 5,294 5,406 38% 33% 31% 45% 5,018 2,000 40% 29% 35% 1,500 30% 25% 1,000 20% 15% 500 10% 2,316 2,014 1,564 2,045 1,944 5% 0 0% FY 21 FY 22 FY 23 FY 24 FY 2
Slide 17: Strong Financial Performance - FY25
Strong Financial Performance - FY25 Advanced enzymes Where ENZYME Is Life Net Working Capital (Days) Net Worth (? mn) 146 14,209 132 135 135 13,241 L 120 12,351 10,886 9,709 FY 21 FY 22 FY 23 FY 24 FY 25 FY 21 FY 22 FY 23 FY 24 FY 25 ROE (%) & ROCE (%) Net Debt to Equity (x) 21.94% 0.02 0.02 0.02 15
Slide 18: Balance Sheet (Consolidated)
Balance Sheet (Consolidated) Advanced enzyi77705 :\> IV FY25 FY24 FY23 FY22 FY21 Particulars Audited Audited Audited Audited Audited Assets Property, plant and equipment 2,929 2,765 2,732 2,622 2,462 Capital work-in-progress 217 411 215 151 102 Intangible assets 523 479 550 609 693 Goodwill 3,334 3,
Slide 19: Annexure
co) — S x< od) = S <x
Slide 20: Company Overview
Company Overview ^^ ancpcl enzymes Where ENZYME is Life Advanced Enzymes is a research driven company with global <fg> leadership in the manufacturing of enzymes and probiotics. We are committed to providing eco-safe solutions to a wide variety of industries like human health care and nutrition, ani
Slide 21: A Rising Global Star
Advanced Enzyme Technologies Limited - A Rising Global Star Advanced enzy 77705 > : \ IV: 9 7 1st 2nd 2nd R&D Units Manufacturing Units Indian enzyme Highest market Listed integrated India – 5 | USA – 1 | India - 8USA - 1 company share in India enzyme player globally Germany –1 68+ 400+ 700+ 45+ 750
Slide 22: Brief History and Evolution
Brief History and Evolution Advanced enzyi77705 :\ IV> Incorporated as R&D locations Advanced • Equity investment • Floated IPO • 4 food enzymes got • Received NIH grant • Received approval Advanced (Thane and Sinnar) Biochemicals Ltd. is by Kotak Private • Acquired 70% stake approved as a for Immun
Slide 23: Board of Directors
Board of Directors Advanced enzyi77705 :\> IV Mr. Vasant Rathi Mr. Mukund M. Kabra Mr. Pramod Kasat Ms. Rasika Rathi Mr. Vinod Jajoo Promoter Chairman Whole-time Director Independent Director Non-Executive Director Independent Director and Non-Executive Director Mr. Sunny Sharma Ms. Rajshree Patel M
Slide 24: Management Team
Management Team Advanced enzyi77705 :\> IV Mr. Beni Prasad Rauka Mr. Dipak Roda Mr. Harshad Doshi Ms. Rasika Rathi Chief Financial Officer Vice President / Market CFO & COO - Advanced Enzymes, USA General Counsel / Vice President & Business Development And Secretary – Advanced Enzymes, USA r- V t f-
Slide 25: How Big is the Opportunity?
How Big is the Opportunity? enzymes Wherr FN7YMFn Life o Global Probiotics Market Global Enzymes Market Animal Probiotics $1Bn 7% $16 Bn Grow at a CAGR Grow at a CAGR 14.12% 7.80% $4.55Bn CY 2024-29 till 2029 $8Bn $13Bn Human Probiotics $12Bn 93% $3.57Bn $3.57Bn Competitive Scenario in the Global En
Slide 26: What we are Aiming in the Opportunity?
What we are Aiming in the Opportunity? Advanced enzyi77705 :\> IV AETL’s Current Share of Revenue Addressable market for AETL CARG(%) over next Focus Area Opportunity Size over next 5 years** 5 years FY25 FY24 Human Nutrition Pharma/API $ 80 mn $ 50 mn 6% $ 18.04 mn, 24% $ 20.32 mn, 27% Probiotics $
Slide 27: What Makes AETL a Unique Investment Case?
What Makes AETL a Unique Investment Case? Advanced enzy 77705 > : \ IV: Integrated Player Specialized Significant Focus with Presence Business with on International Across the High Entry Markets & Brand Enzyme Barriers Building Value Chain Inherent Strong Research Diversification Strong Financial &
Slide 28: Integrated Player with Presence Across the Enzyme Value Chain
Integrated Player with Presence Across the Enzyme Value Chain Advanced enzy 77705 > : \ IV: Research & Development Manufacturing Marketing & Distribution . co Earnings Presentation | November 2025 27
Slide 29: Specialized Business With High Entry Barriers
Specialized Business With High Entry Barriers Advanced enzyi77705 :\> IV Technocrat Promoters Global Competitiveness Cumulative experience of 7+ decades Amongst the Lowest Cost Manufacturers in the in the global enzyme industry World (Benchmarked both in terms of Capex & Opex) Sustained Research & D
Slide 30: Future Growth Drivers
Future enzymes Whore ENZYME is Life Growth Drivers Continued Broaden & Deepen Inorganic Investment in R&D Geographical Presence Expansion o Acquisition of Key Technologies, Competencies & o Identify Product gaps and Develop new Enzymes, o Increased focus on high return applications where Skill-sets
Slide 31: Focus Areas Going Ahead
Focus enzymes • ZiU' tP ' /• Areas Going Ahead Animal Nutrition Probiotics Bio-Catalysis Baking k <4 11» AMb l£ m!®* • Continuing conduct trials and studies to bring • To introduce more probiotics products in • Developing bio catalysis for API manufacturers, • In Bio-processing division, our focus i
Slide 32: Shareholders Information
Shareholders Information Advanced enzymes Where ENZYME Is Life Stock Data Stock Chart 4 Market Capitalization (₹) 36,440 mn 437.30 Shares Outstanding 111.88 mn 325.70 Symbol (NSE/ BSE) ADVENZYMES / 540025 Sep-24 Oct-24 Nov-24 Dec-24 Jan-25 Feb-25 Mar-25 Apr-25 May-25 Jun-25 Jul-25 Aug-25 Sep-25 Sour
Slide 33: Thank you
Thank you Advanced Enzyme Technologies Limited . . iddka Address: 5th Floor, 'A' wing, Sun Magnetica LIC Service Road, Louiswadi, Thane (W) 400 604, India Tel: +91-22-4170 3200 Fax: + 91-22-25835159 Web: www.advancedenzymes.com CIN No: L24200MH1989PLC051018 • Advanced Enzyme . ^ Dnyan Sun Crest Cont